Meanwhile, our work highlighted the crucial prognostic value of FOXP3 in predicting relapse of SCLC at stages I–III, constructed an immune risk score system, and explored FOXP3-based clinical prediction model by integrating immune risk score and SCLC staging. Here, FOXP3 is linked to small cell lung carcinoma.